Polyrizon Ltd.
PLRZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.03M
Close$
$0.81
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.03 Million |
|---|---|
| Enterprise Value | $13.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.07 |
| Beta | -1.53 |
| Outstanding Shares | 1,608,266 |
Return
| Return on Equity | -19.60% |
|---|---|
| Return on Assets | -19.20% |
| Return on Invested Capital | -22.49% |
Valuation & Multiples
| P/E Ratio | -3.84 |
|---|---|
| PEG | -1.67 |
| Price to Sales | - |
| Price to Book Ratio | 1.18 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.91 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 1, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.14%▼ 4.14% |
|---|---|
| Total Invested | $13,372▼ 95.12% |
| Investors Holding | 2▼ 2.00% |
ESG Score
No data
About Polyrizon Ltd.
2 employees
CEO: Mr. Tomer Izraeli Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithel...